What is the recommended dosage of Amitiza (lubiprostone) for an adult?

Amitiza Dosage for Adults

For chronic idiopathic constipation (CIC), the recommended dose is 24 mcg twice daily; for irritable bowel syndrome with constipation (IBS-C), use 8 mcg twice daily; and for opioid-induced constipation (OIC), use 24 mcg twice daily 1.

Dosing by Indication

Chronic Idiopathic Constipation (CIC)

• Standard dose: 24 mcg twice daily 2, 1
• Take with food and water to minimize nausea 2
• Effects typically manifest within 2 days in responders 2
• No maximum duration specified in drug labeling 2

Irritable Bowel Syndrome with Constipation (IBS-C)

• Dose: 8 mcg twice daily 2, 1
• FDA-approved for adult women only 1

Opioid-Induced Constipation (OIC)

• Dose: 24 mcg twice daily 1

Special Population Adjustments

Hepatic Impairment

This is critical—dose reduction is mandatory in hepatic dysfunction:

• Moderate hepatic impairment (Child-Pugh Class B): Reduce to 8 mcg twice daily for CIC and OIC 1
• Severe hepatic impairment (Child-Pugh Class C): Reduce to 8 mcg twice daily for all indications 1
• Mild hepatic impairment (Child-Pugh Class A): No adjustment needed 1

The rationale: Patients with moderate and severe hepatic impairment experience markedly elevated systemic exposure of the active metabolite M3 (119% and 521% increases respectively), with corresponding increases in adverse events 1.

Elderly Patients (≥65 years)

• No dose adjustment required 1
• Elderly patients actually experienced lower rates of nausea (19% vs 29% in overall population) 1
• Efficacy is comparable to younger patients 2, 1

Administration Guidelines

• Always take with food and water to reduce nausea risk 2
• The nausea risk is dose-dependent and significantly lower when taken with meals 2
• Contraindicated in mechanical GI obstruction 2

Common Pitfalls to Avoid

1. Don't use the CIC dose (24 mcg) for IBS-C—the approved dose is 8 mcg twice daily for IBS-C 2, 1
2. Don't forget hepatic dose adjustments—failure to reduce the dose in moderate/severe hepatic impairment leads to substantially increased adverse events 1
3. Don't take on an empty stomach—this significantly increases nausea, the most common side effect (35% incidence) 2

Clinical Context

Lubiprostone is a chloride channel-2 activator that increases intestinal fluid secretion without altering serum sodium and potassium 2. The 2023 AGA-ACG guidelines provide a conditional recommendation for lubiprostone in adults with CIC who don't respond to over-the-counter agents, based on low certainty evidence 2. While it increases spontaneous bowel movements per week (mean difference 1.98) and responder rates, there is an increased risk of diarrhea leading to discontinuation 2.